Arrowhead gets $35m bargain for Novartis RNAi assets with Alnylam targets
This article was originally published in Scrip
Arrowhead Research president and CEO Christopher Anzalone courted Novartis for more than a year before the Pasadena, California-based biotechnology company signed an agreement to buy the Novartis's RNA interference (RNAi) portfolio, but he doesn't expect the $35m acquisition to immediately yield new clinical programs.
You may also be interested in...
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Shares in US biotech Arrowhead Pharmaceuticals took a tumble after the FDA put a clinical hold on one of its small interfering RNAs (siRNAs) Phase II programs in hepatitis B because of concerns over a delivery vehicle that is also used in two of its other Phase II candidates.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.